What is XenoPort Profitability Rank?
XenoPort has the Profitability Rank of 0.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
XenoPort's Operating Margin % for the quarter that ended in Mar. 2016 was -97.29%. As of today, XenoPort's Piotroski F-Score is 0.
Competitive Comparison of XenoPort's Profitability Rank
For the Biotechnology subindustry, XenoPort's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XenoPort's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XenoPort's Profitability Rank distribution charts can be found below:
* The bar in red indicates where XenoPort's Profitability Rank falls into.
XenoPort Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
XenoPort has the Profitability Rank of 0.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
XenoPort's Operating Margin % for the quarter that ended in Mar. 2016 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
XenoPort has an F-score of 0. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
XenoPort (XenoPort) Business Description
Traded in Other Exchanges
N/A
Address
XenoPort Inc is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological and other disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in Japan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson's disease. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign countries in which it may commercialize its products.
Executives
| William Jl Rieflin |
director |
NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
| Cathy Friedman |
director |
C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005 |
| Wendall Wierenga |
director |
12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
| Dennis M Fenton |
director |
|
| William G Harris |
officer: See Remarks |
C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051 |
| Jeryl L Hilleman |
director |
C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
| John Gordon Freund |
director |
125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301 |
| Paul L Berns |
director |
11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020 |
| Deerfield International Master Fund, L.p. |
10 percent owner, other: Possible Member of 10% Group |
780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
| Deerfield Management Company, L.p. (series C) |
10 percent owner, other: Possible Member of 10% Group |
345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
| James E Flynn |
10 percent owner, other: Possible Member of 10% Group |
780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
| Deerfield Partners, L.p. |
10 percent owner, other: Possible Member of 10% Group |
345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
| Deerfield Mgmt L.p. |
10 percent owner, other: Possible Member of 10% Group |
780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
| Deerfield Special Situations Fund, L.p. |
10 percent owner, other: Possible Member of 10% Group |
780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
| Ronald W Barrett |
director, officer: Chief Executive Officer |
C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051 |
XenoPort (XenoPort) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XNPT has been successfully added to your